Upstream Bio (UPB) Projected to Post Earnings on Thursday

Upstream Bio (NASDAQ:UPBGet Free Report) is expected to be posting its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Upstream Bio to post earnings of ($0.56) per share for the quarter.

Upstream Bio Price Performance

NASDAQ UPB opened at $7.73 on Wednesday. Upstream Bio has a 52-week low of $6.65 and a 52-week high of $29.46. The stock’s 50-day moving average is $12.14.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Piper Sandler assumed coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They set an “overweight” rating and a $75.00 price objective for the company. TD Cowen assumed coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They set a “buy” rating for the company. JPMorgan Chase & Co. started coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They set an “overweight” rating and a $38.00 price objective for the company. Finally, William Blair started coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They set an “outperform” rating for the company.

Check Out Our Latest Report on Upstream Bio

About Upstream Bio

(Get Free Report)

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.

See Also

Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.